Name: Date of Birth: Phone: ( ) Gender: Mailing Address:

Similar documents
Medication Guide LATUDA (luh-too-duh) (lurasidone hydrochloride) Tablets

MEDGUIDE SECTION. What is the most important information I should know about SEROQUEL? SEROQUEL may cause serious side effects, including:

Medication Guide. What is the most important information I should know about ZYPREXA? ZYPREXA may cause serious side effects, including:

Medication Guide SYMBYAX. (SIM-be-ax)

These are just some of the eligibility requirements meeting these criteria does not guarantee acceptance.

What You Need to Know About Xenazine

Medication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules

MEDICATION GUIDE. Bupropion Hydrochloride (bue-proe-pee-on HYE-droe-KLOR-ide) Extended-Release Tablets, USP (SR)

MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets

MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets

Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)

MEDICATION GUIDE. TRINTELLIX [trin -tel-ix] (vortioxetine) Tablets

Medication Guide KLONOPIN (KLON-oh-pin) (clonazepam) Tablets

MEDICATION GUIDE. Tranxene* (TRAN-zeen) T-TAB (clorazepate dipotassium) tablets

MEDICATION GUIDE POTIGA (po-tee-ga) tablets, CV (ezogabine)

Bristol-Myers Squibb Access Support Program. What Medications does the BMS Access Support Program help with? Program Registration Steps

MEDICATION GUIDE WELLBUTRIN XL * (WELL byu-trin) (bupropion hydrochloride extended-release tablets)

Below, this letter outlines [patient name] s medical history, prognosis, and treatment rationale.

MEDICATION GUIDE KOMBIGLYZE XR (kom-be-glyze X-R) (saxagliptin and metformin HCl extended-release) tablets

Bayer HealthCare Patient Assistance Program. Program Guidelines & Application Form

It is important that you tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose.

MEDICATION GUIDE. (topiramate) Tablets. Sprinkle Capsules

Can one pill a day help lower your blood sugar?

Application Form Instructions

Humulin (HU-mu-lin) R

MEDICATION GUIDE Trokendi XR (tro-ken-dee eks ahr) (topiramate) Extended-release Capsules

Haloperidol: MedlinePlus Drug Information

Trileptal (Oxcarbazepine)

Ask your healthcare provider about LONG-ACTING AVEED (testosterone undecanoate) AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR. Not an actual patient.

MEDICATION GUIDE ZYBAN (zi ban) (bupropion hydrochloride) Sustained-Release Tablets

1. LAMICTAL may cause a serious skin rash that may cause you to be hospitalized or even cause death.

MEDICATION GUIDE. TOPAMAX (TOE-PA-MAX) (topiramate) Tablets and Sprinkle Capsules

About the Program 1. What is the current Osphena (ospemifene) Savings Offer for 30 day prescription?

MEDICATION GUIDE SYLATRON (SY-LA-TRON) (Peginterferon alfa-2b)

Medication Guide. Cymbalta. (duloxetine delayed-release capsules)

Medication Therapy Management Program. A service for better understanding and managing the drugs you take at no additional cost to you.

N HUMAN Novo Nordisk Patient Information for Novolin N

Share the important information in this Medication Guide with members of your household.

Revised 7/05. Copyright 2005 St. Jude Children's Research Hospital Page 1 of 6

How To Safely Use Aripiprazole

VALIUM PRODUCT MONOGRAPH. diazepam. 5 mg Tablets. Anxiolytic-sedative. Date of Revision: February 7, 2014

Remeron (mirtazapine)

MEDICATION GUIDE ACTOPLUS MET (ak-tō-plus-met) (pioglitazone hydrochloride and metformin hydrochloride) tablets

Package leaflet: Information for the user

MEDICATION GUIDE SUBOXONE (Sub-OX-own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII)

STRATTERA (Stra-TAIR-a)

PHARMACIST DETACH HERE AND GIVE TO PATIENT

The following is a sample of psychotropic drug warnings that drug regulatory agencies

MEDICATION GUIDE. These serious side effects are described below:

Prescription Drug Abuse

What you should know about treating your pain with opioids. Important information on the safe use of opioid pain medicine.

Zyprexa (olanzapine)

Enroll in Interconnect

Co-Pay Assistance Program for CUBICIN (daptomycin for injection) for Intravenous Use Enrollment Form

Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets

Help us process your applications faster

Application Form Instructions

Medication Guide TASIGNA (ta-sig-na) (nilotinib) Capsules

MEDICATION GUIDE POMALYST (POM-uh-list) (pomalidomide) capsules. What is the most important information I should know about POMALYST?

Patient Medication Guide Brochure

SUPPORT PATH PROGRAM INTAKE FORM PHONE: FAX:

Schizophrenia National Institute of Mental Health

Complete the enrollment form on the reverse side to join Onyx 360 today.

Thorazine (chlorpromazine)

What you need for Your to know Safety about longterm. opioid pain care. What you need to know about long-term opioid

MEDICATION GUIDE Xyrem (ZĪE-rem) (sodium oxybate) oral solution CIII

Welcome to OptumRx Your Prescription Benefit Program

Prochlorperazine 3 mg Buccal Tablets (PROCHLORPERAZINE MALEATE)

making sense of psychiatric medication making sense psychiatric medication

Management of Diabetes

MEDICATION GUIDE JUXTAPID (JUKS-tuh-pid) (lomitapide) capsules

HUMULIN R REGULAR INSULIN HUMAN INJECTION, USP (rdna ORIGIN) 100 UNITS PER ML (U-100)

1. What Olanzapine Tablets is and what it is used for

PATIENT INFORMATION LEAFLET

Electroconvulsive Therapy - ECT

Southwestern Foot & Ankle Associates, P.C Parkwood Blvd, Suite 602 Frisco, TX Phone: Fax: Dr. Thomas H.

Health Information Sheet

NOVARTIS SERVICE REQUEST FORM FOR PATIENT SUPPORT

Memantine (Ebixa) Drug treatment for Alzheimer s disease

Type 2 Diabetes Type 2 Diabetes

Your Pharmacy Benefit: Make it Work for You!

MEDICATION GUIDE. What is Morphine Sulfate Oral Solution?

Asenapine (Saphris) for bipolar I disorder

Medicines To Treat Alcohol Use Disorder A Review of the Research for Adults

MEDICATION GUIDE STELARA

Administer a quarter of usual dose Strong CYP2D6 or CYP3A4 inhibitors Administer half of usual dose Strong CYP2D6 and CYP3A4 inhibitors

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

Copayment Is Due At Time Of Visit. Self-pay (payment due at time of service)

OPIOID PAIN MEDICATION Agreement and Informed Consent

Clinical Trials Network

REGISTRATION FORM. How would you like to receive health information? Electronic Paper In Person. Daytime Phone Preferred.

AUBAGIO Conversation Starter

Understanding Antipsychotic Medications

Cocaine. Like heroin, cocaine is a drug that is illegal in some areas of the world. Cocaine is a commonly abused drug.

Ask Your Doctor if There May Be a SMARTER CHOICE

Section II When you are finished with this section, you will be able to: Define medication (p 2) Describe how medications work (p 3)

Dr. David Y. Liao, D.O. Orthopedic Center, LLC. Release of Information

Transcription:

To apply for help in affording your Sunovion prescription, please mail or fax a completed application to: Sunovion Support Prescription Assistance Program ( Program ) PO Box 220285, Charlotte, NC 28222-0285 -or- Fax: (877) 850-0821 Remember to include both your signature and that of your doctors, proof of income and your prescription. If you have any questions or need help filling out this form, please contact us at (877)850-0819 or visit www.sunovionsupport.com. Patient Information Name: Date of Birth: Phone: ( ) Gender: Mailing Address: City: State: Zip: Household Income Information 1. Is the patient a US resident (includes Puerto Rico)? YES NO 2. Is the patient 18 years of age or older? YES NO 3. Number of people in household: (include yourself, your spouse and any dependents) 4. What is total GROSS ANNUAL household income (including Social Security, Disability, Veterans, Wages, pension benefits, etc.)? $ 5. Did the patient file a Federal Income Tax Return for previous calendar year? YES NO Please provide us with one of the following items to show total gross annual income: Current paycheck stubs, proof of Social Security Income, 1099 or W-2 forms for all members of household Federal Tax Return ( form 1040 or 1040EX) for prior tax year If the patient has not filed a Federal Tax Return, visit www.irs.gov to request a free Verification of Non-Filing. Click on "Order a Transcript" or call 1-800-908-9946. Use Form 4506-T and check box 7 to request verification of non-filing. 1

Patients Insurance Information 1. Is the patient enrolled in Medicare/Medicaid? YES NO 2. Does the patient have prescription drug coverage through any other benefit program that helps pay for prescription medicine, such as private insurance or VA or military benefits, including Medicare Part D? YES NO If yes: please describe: From the Healthcare Professional (to be completed by the doctor who is prescribing the medicine) *Healthcare Professional: HCCE permit # ( required in state of FL only) Site contact: State License #: Facility Name: Phone: ( ) Fax: ( ) Street address: City: State: Zip: *If Treating Provider is not an MD please provide required supporting documentation authorizing prescribing of and receiving of prescription medication. Please visit the website www. NABP.net if you have questions as to what your state may require for you to receive medication shipped directly to you. All required documentation is required to ship the medication. Prescription Information: Latuda (lurasidone HCl) Please see Important Safety Information, including Boxed Warnings on pages 4 and 5 and enclosed full Prescribing Information. Dosage: 20mg/day 40mg/day 60mg/day 80mg/day 120mg/day 160mg/day* Day Supply: 30 Days 60 Days 90 days Method of delivery: Prescription to be shipped directly to healthcare professional s address provided on page 3 Patient will pick up prescription at retail pharmacy ( will receive 30 day supply/ per fill only) Number of Refills (max 11): 2

Your Consent is Required to Process Application I acknowledge and agree that the above information is complete and accurate. I attest that I have no prescription insurance coverage, including Medicaid, Medicare or other public or private program, and I have insufficient financial resources to pay for the prescribed product. I understand and acknowledge that this assistance is temporary and that this program may be changed or discontinued at any time without notice. Patients Signature: Date: If you cannot sign, a Legal Guardian may sign for you. Representatives Name: Representatives Signature: Date: Describe relationship to Applicant: Healthcare Professional Signature is Required to Process Application for the Sunovion Support Prescription Assistance Program My signature below certifies that the person named in this form is my patient and medication received from the Program is only for that patient s use as indicated by the US Food and Drug Administration, and the information provided, to my knowledge, is accurate. I understand this Program is only for LATUDA and it will not be offered for sale, trade, or barter. I agree that I will not submit any claim for reimbursement concerning the Product to Medicare, Medicaid, or any other third party, or return such Product for credit. I also agree that the Program has the right at any time to contact my patient, to modify or terminate the Program, and to recall or discontinue Product without notice. To the best of my knowledge, my patient does not have prescription drug insurance coverage (including Medicare, Medicaid, county funded, or other public programs) for the product being requested. Letter of Affiliation: I certify that I am (a) affiliated with the entity(ies) and location(s) identified on this application, (b) will be responsible in all respects for the receipt and accountability of the pharmaceutical products shipped to this entity at such location, and (c) will immediately notify the Program if either of the foregoing statements is no longer true. Please indicate affiliated shipping address for Healthcare professional where the medication will be shipped: Healthcare Professional Name: Street Address: City: State: Zip: Phone: Healthcare Professional Signature: Date: 3

Important Safety Information and indications for LATUDA INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS Elderly patients with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) treated with this type of medicine are at an increased risk of death compared to patients receiving placebo (sugar pill). LATUDA is not approved for treating elderly patients with dementia-related psychosis. Antidepressants have increased the risk of suicidal thoughts and actions in some children, teenagers, and young adults. Patients of all ages starting treatment should be watched closely for worsening of depression, suicidal thoughts or actions, unusual changes in behavior, agitation, and irritability. Patients, families, and caregivers should pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. Report any change in these symptoms immediately to the doctor. LATUDA is not approved for patients under the age of 18 years. LATUDA can cause serious side effects, including stroke that can lead to death, which can happen in elderly people with dementia who take medicines like LATUDA. Neuroleptic malignant syndrome (NMS) is a rare but very serious condition that can happen in people who take antipsychotic medicines, including LATUDA. NMS can cause death and must be treated in a hospital. Call your healthcare provider right away if you become severely ill and have some or all of these symptoms: high fever, excessive sweating, rigid muscles, confusion, or changes in your breathing, heartbeat, or blood pressure. Tardive dyskinesia (TD) is a serious and sometimes permanent side effect reported with LATUDA and similar medicines. Tell your doctor about any movements you cannot control in your face, tongue, or other body parts, as they may be signs of TD. TD may not go away, even if you stop taking LATUDA. TD may also start after you stop taking LATUDA. Increases in blood sugar can happen in some people who take LATUDA. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes (such as being overweight or a family history of diabetes), your healthcare provider should check your blood sugar before you start LATUDA and during therapy. Call your healthcare provider if you have any of these symptoms of high blood sugar (hyperglycemia) while taking LATUDA: feel very thirsty, need to urinate more than usual, feel very hungry, feel weak or tired, feel sick to your stomach, feel confused, or your breath smells fruity. Increases in triglycerides and LDL (bad) cholesterol and decreases in HDL (good) cholesterol have been reported with LATUDA. You may not have any symptoms, so your healthcare provider may decide to check your cholesterol and triglycerides during your treatment with LATUDA. Some patients may gain weight while taking LATUDA. Your doctor should check your weight regularly. Tell your doctor if you experience any of these: feeling dizzy or light-headed upon standing, decreases in white blood cells (which can be fatal), trouble swallowing. LATUDA and medicines like it may raise the level of prolactin. Tell your healthcare provider if you experience a lack of menstrual periods, leaking or enlarged breasts, or impotence. 4

Tell your healthcare provider if you have a seizure disorder, have had seizures in the past, or have conditions that increase your risk for seizures. Tell your healthcare provider if you experience prolonged, abnormal muscle spasms or contractions, which may be a sign of a condition called dystonia. LATUDA can affect your judgment, thinking, and motor skills. You should not drive or operate hazardous machinery until you know how LATUDA affects you. LATUDA may make you more sensitive to heat. You may have trouble cooling off. Be careful when exercising or when doing things likely to cause dehydration or make you warm. Avoid eating grapefruit or drinking grapefruit juice while you take LATUDA since these can affect the amount of LATUDA in the blood. Tell your healthcare provider about all prescription and over-the-counter medicines you are taking or plan to take, since there are some risks for drug interactions with LATUDA. Tell your healthcare provider if you are allergic to any of the ingredients of LATUDA or take certain medications called CYP3A4 inhibitors or inducers. Ask your healthcare provider if you are not sure if you are taking any of these medications. Avoid drinking alcohol while taking LATUDA. Tell your healthcare provider if you are pregnant or if you are planning to get pregnant. Avoid breastfeeding while taking LATUDA. The most common side effects of LATUDA include sleepiness or drowsiness; restlessness or feeling like you need to move around (akathisia); difficulty moving, slow movements, muscle stiffness, or tremor; and nausea. These are not all the possible side effects of LATUDA. For more information, ask your healthcare provider or pharmacist. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. INDICATIONS LATUDA is used to treat adult patients with: Depressive episodes in bipolar I disorder (bipolar depression) when used alone or with lithium or valproate Schizophrenia Thank you for your interest in Sunovion Pharmaceuticals Inc. You are receiving this information due to your registration for a previous Sunovion program or because you are a healthcare provider that prescribes or may prescribe Sunovion products. Sunovion Pharmaceuticals Inc. respects your personal information and complies with applicable laws regarding the use of such information. Sunovion will not sell or transfer your name to any third-party for their marketing use. Please see the most recent version of our privacy policy which may change from time to time at www.sunovion.com/util/privacy.html. If you decide you no longer wish to receive mail from Sunovion, you may opt out at any time by notifying us at 1-888-394-7377 or by emailing info@sunovion.com LATUDA and are registered trademarks of Dainippon Sumitomo Pharma Co. Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. 2014 Sunovion Pharmaceuticals Inc. All rights reserved 5

Authorization and Consent to Share and Disclose Health Information with the Sunovion Support Prescription Assistance Program ( Program ) Please read and sign this form so that you or the person for whom you are assisting may be able to participate in the Program. Please note I is defined as the potential Participant. I acknowledge and agree that all the information I provide in connection with my application to the Program will be used to decide if I qualify for the Program. By signing below, I verify that the information on my application, including a copy of my proof of income documentation, is complete and accurate. I do not have any other coverage for prescription medications, including Medicaid, Medicare, or any public or private assistance programs or any other prescription insurance. I understand that any changes to my financial, prescription drug coverage, or insurance information may affect whether I am able to continue to participate in the Program. I agree to contact the Program to inform them of any changes to my income, prescription drug coverage, or insurance information. I allow my healthcare provider(s), my pharmacy(ies), and my health plan or insurers, to give medical information relating to my use or need for product(s) provided under the Program to The Lash Group, Inc. The Lash Group runs the Program on behalf of Sunovion Pharmaceuticals Inc. My medical information can include spoken or written facts about my health and payment benefits. It can include copies of records from my health provider, pharmacy, or health plan about my health or health care. People who work for The Lash Group and the Program may see my information, but they may use it only to help me get assistance to receive my Sunovion medication, to determine whether I qualify for the Program, to operate the Program, or as otherwise required or permitted by law. I allow The Lash Group and the Program the right to verify and to evaluate any financial documentation, insurance information, and medical records submitted to the Program to determine if I qualify for the Program and to operate the Program. I understand that The Lash Group and the Program have the right to contact me directly to confirm receipt of medications [or to obtain my feedback about the Program] and that the Program can revise, change, or terminate the Program at any time. I understand that I may cancel my permission and withdraw from this Program at any time. I understand that if I cancel my permission I can tell my healthcare provider, my pharmacy, and my insurer in writing that I do not want them to share any more information with The Lash Group and the Program, but it will not change any actions they took before I told them and it will terminate my participation in the Program. This authorization and consent will last for up to12 months. I know that I have a right to see or copy the information my health care providers, my pharmacy, or insurers have given to The Lash Group and the Program. I understand that I am free at any time to switch my healthcare provider and it will not affect eligibility for financial assistance. This Program is offered to me regardless of any healthcare provider or pharmacy I use. I KNOW THAT I MAY REFUSE TO SIGN THIS FORM. My choice about whether to sign this form will not change the way my health care providers, pharmacies, or insurers treat me. If I refuse to sign this form, I know that this means I will not be eligible to participate in the Program. I understand that signature of a legal guardian or parent is required for all minor applicants. Applicant Signature: Date: Applicant Name: If you are unable to sign or are a minor, under the age of 18, a parent or legal guardian must also sign. Representatives Name: Date: Representatives Signature: Describe relationship to Applicant: If someone helped you with the application and you want them to answer questions for you, please give us their name and phone number: Name: Phone: PO Box 220285 Charlotte, NC 28222-0285 Phone (877)850-0819 Fax (877)850-0821 SUNOVION, and are registered trademarks of Dainippon Sumitomo Pharma Co. Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. 2014 Sunovion Pharmaceuticals Inc. All rights reserved.